Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Genomic DNA serves as the fundamental repository of genetic information within the cell nucleus, organized into complex chromosomal structures. The N7 positions of the purine bases, guanine and adenine, are the most nucleophilic sites in the DNA double helix, making them primary targets for a wide range of electrophilic chemotherapeutic agents (StatPearls: Alkylating Agents, 2023). When drugs such as nitrogen mustards or platinum complexes bind to these sites, they create covalent adducts and cross-links that interfere with essential biological processes like DNA replication and transcription (Nature Reviews Cancer, 2017). This interference is particularly lethal to rapidly dividing cancer cells, which have less time to repair DNA damage before attempting mitosis. However, because these interactions are not specific to malignant cells, they often lead to significant toxicity in healthy, proliferating tissues such as the bone marrow and gastrointestinal tract (NIH: National Cancer Institute). Furthermore, the permanent modification of DNA in surviving healthy cells carries a risk of mutagenicity, which can lead to the development of secondary cancers years after treatment (Journal of Clinical Oncology, 2020).
Drugs targeting these sites act as electrophiles that form covalent bonds with the nucleophilic N7 atoms of guanine and adenine bases. This process, known as alkylation or platination, results in the formation of DNA adducts and both intrastrand and interstrand cross-links (StatPearls: Alkylating Agents, 2023). These structural modifications physically obstruct DNA polymerase and RNA polymerase, thereby inhibiting DNA replication and RNA transcription (Nature Reviews Cancer, 2017). The resulting DNA damage triggers cellular stress responses and DNA repair pathways; if the damage is irreparable, it leads to cell cycle arrest and the induction of apoptosis via p53-dependent and independent pathways (PubMed: PMC3077086).
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Genomic DNA (N7 of guanine and adenine) (gDNA).